article thumbnail

Phase 3 trial data confirm efficacy and safety profile of R21/Matrix-M malaria vaccine in African children

Express Pharma

The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75 per cent efficacy in African children.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Immunity 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. In lupus, the body’s immune system starts to attack its own cells. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Immunity 144
article thumbnail

BMS swoops on Forbius, snaring another immuno-oncology player

pharmaphorum

Since its foundation in 2011, privately-held Forbius has been working on drugs that inhibit TGF beta 1 and 3, two targets thought to play a role in protecting cancers from attack by the immune system and the development of fibrosis (scarring).

article thumbnail

BMS’ Orencia gets FDA nod for GvHD thanks to real-world data

pharmaphorum

Orencia (abatacept) becomes the first drug to be approved to prevent GvHD , a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow transplant. billion in the first nine months of the year.

Immunity 105
article thumbnail

ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?

Pharmaceutical Technology

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. More recently, ICIs have also been approved for resectable cutaneous melanomas as adjuvant therapy, following surgical resection.

article thumbnail

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. He then worked at BCG from 2004 to 2011, where he developed expertise in the energy, engineering, and high-tech sectors.